tradmap

TNYA Earnings Tenaya Therapeutics, Inc.

Reported EPS, revenue and net income by fiscal period (SEC EDGAR) — quarterly and annual. Full financials → Chart & overview → Updated

Annual results

Diluted EPS (annual)
-$4 -$2 $0 2021 2022 2023 2024 2025
EPS
Net income (annual)
-$124M -$62M $0 2020 2021 2022 2023 2024 2025
Net income
Return on equity (annual)
-120% -36% 47% 0% 2020 2021 2022 2023 2024 2025
ROE

Quarterly results

Diluted EPS (quarterly)
-$2 -$1 $0 Q3 '22 Q2 '23 Q1 '24 Q3 '24 Q2 '25 Q1 '26
EPS
Revenue (quarterly)
$0 $555000 $1M Q3 '23 Q1 '24 Q3 '24 Q1 '25 Q3 '25 Q1 '26
Revenue
Net income (quarterly)
-$43M -$22M $0 Q3 '23 Q1 '24 Q3 '24 Q1 '25 Q3 '25 Q1 '26
Net income

Reported EPS history

1–20 of 20
Q2 20262026-06-30-0.292026-08-0510-Q
Q1 20262026-03-31-0.092026-05-0610-Q
FY 20252025-12-31-0.592026-03-1110-K
Q3 20252025-09-30-0.482025-11-1010-Q
Q2 20262025-06-30-0.372026-08-0510-Q
Q1 20262025-03-31-0.242026-05-0610-Q
FY 20252024-12-31-1.312026-03-1110-K
Q3 20252024-09-30-1.042025-11-1010-Q
Q2 20252024-06-30-0.742025-08-0610-Q
Q1 20252024-03-31-0.402025-05-0710-Q
FY 20242023-12-31-1.682025-03-1010-K
Q3 20242023-09-30-1.282024-11-0610-Q
Q2 20242023-06-30-0.892024-08-0810-Q
Q1 20242023-03-31-0.432024-05-1410-Q
FY 20232022-12-31-2.762024-03-1810-K
Q3 20232022-09-30-2.182023-11-0810-Q
Q2 20232022-06-30-1.442023-08-0910-Q
Q1 20232022-03-31-0.752023-05-1010-Q
FY 20222021-12-31-4.102023-03-0810-K
Q3 20222021-09-30-4.752022-11-1010-Q

Source: SEC EDGAR / XBRL (reported actuals; no consensus estimates). Some issuers (e.g. mortgage REITs, banks) don't report a conventional revenue line, so those charts may be omitted. Informational only — not financial advice.